Antiphospholipid antibodies and subclinical interstitial lung disease in the MESA cohort

Claire McGroder; Ganesh Raghu; Anna J. Podolanczuk

doi:10.1186/s12931-025-03395-3

November 28, 2025Respiratory ResearchOpen Access

Antiphospholipid antibodies and subclinical interstitial lung disease in the MESA cohort

View Full Paper

Ask AI

Bookmark

Share

Key Points

Inflammation and fibrosis were identified as key outcomes linked to antiphospholipid antibodies.
The study found that higher levels of these antibodies corresponded with increased lung injury metrics.
Analysis involved participants from the MESA cohort, using standardized measurements of lung function and injury.
Findings highlight the potential risks associated with antiphospholipid antibodies and lung health.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis shows inflammation and fibrosis associated with antiphospholipid antibodies in the MESA cohort, suggesting a link to lung injury.

Abstract

Antiphospholipid antibodies are associated with HAA, a quantitative measure of lung injury, inflammation and fibrosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

McGroder et al. (2025) studied this question.

synapsesocial.com/papers/692e3d8d6c9b3ab28c1875c5 https://doi.org/10.1186/s12931-025-03395-3

View Full Paper

Ask AI

Bookmark

Share

Antiphospholipid antibodies and subclinical interstitial lung disease in the MESA cohort

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Antiphospholipid antibodies and subclinical interstitial lung disease in the MESA cohort

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading